BioMarin: So You’re Saying There’s a Chance?

Oppenheimer’s Christopher Marai and Michelle Gilson call BioMarin’s (BMRN) appearance before an FDA panel considering its Duchenne muscular dystrophy drug a “disaster” but argue there’s still a chance it will be approved. They explain why: Al Drago/CQ Roll Call/Getty Images We attended the FDA advisory meeting for Kyndrisa yesterday. The panel was ultimately a disaster, dominated by […]